Viral hepatitis in the office of G. P.
Authors:
P. Husa
Authors‘ workplace:
Klinika infekčních chorob LF MU a Fakultní nemocnice Brno
přednosta doc. MUDr. Petr Husa, CSc.
Published in:
Prakt. Lék. 2006; 86(6): 313-316
Category:
Reviews
Overview
Hepatitis viruses cause diffuse necro-inflammatory liver diseases. They currently present a very serious health problem. Acute and chronic forms of the diseases are the cause of significant morbidity and mortality both in our country as well as abroad. Viral hepatitis A, B, C, and E are of the greatest significance in the Czech Republic. At present, four drugs are approved for the treatment of chronic hepatitis B in the Czech Republic: pegylated interferon alpha-2a, standard interferon alpha, lamivudine, and adefovir dipivoxil. The standard treatment for chronic hepatitis B consists of a combination of pegylated interferon alpha-2a or alpha-2b, and ribavirin. The main task at the moment is to actively search for, and treat, those individuals with chronic hepatitis B and C before the disease reaches its advanced stage, where quality and length of life are significantly affected and the treatment options limited.
Key words:
viral hepatitis, pegylated interferon, standard interferon alpha, lamivudine, adefovir dipivoxil, ribavirin
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2006 Issue 6
Most read in this issue
- The harmful effect of noise on the human organism
- Pulmonary embolism in the pneumology out-patient clinic
- Inhaled insulin
- Why and what kind of physical training is most effective for health and quality of life in older persons?